key: cord-0996818-2wafqugd
authors: Jafari, Maryamsadat; Pormohammad, Ali; Sheikh Neshin, Saeideh Aghayari; Ghorbani, Saied; Bose, Deepanwita; Alimohammadi, Shohreh; Basirjafari, Sedigheh; Mohammadi, Mehdi; Rasmussen‐Ivey, Cody; Razizadeh, Mohammad Hossein; Nouri‐Vaskeh, Masoud; Zarei, Mohammad
title: Clinical characteristics and outcomes of pregnant women with COVID‐19 and comparison with control patients: A systematic review and meta‐analysis
date: 2021-01-02
journal: Rev Med Virol
DOI: 10.1002/rmv.2208
sha: 3c0db4aa2f01bfb491d54b31a1a755855a4969a3
doc_id: 996818
cord_uid: 2wafqugd

In a large‐scale study, 128176 non‐pregnant patients (228 studies) and 10000 pregnant patients (121 studies) confirmed COVID‐19 cases included in this Meta‐Analysis. The mean (confidence interval [CI]) of age and gestational age of admission (GA) in pregnant women was 33 (28–37) years old and 36 (34–37) weeks, respectively. Pregnant women show the same manifestations of COVID‐19 as non‐pregnant adult patients. Fever (pregnant: 75.5%; non‐pregnant: 74%) and cough (pregnant: 48.5%; non‐pregnant: 53.5%) are the most common symptoms in both groups followed by myalgia (26.5%) and chill (25%) in pregnant and dysgeusia (27%) and fatigue (26.5%) in non‐pregnant patients. Pregnant women are less probable to show cough (odds ratio [OR] 0.7; 95% CI 0.67–0.75), fatigue (OR: 0.58; CI: 0.54–0.61), sore throat (OR: 0.66; CI: 0.61–0.7), headache (OR: 0.55; CI: 0.55–0.58) and diarrhea (OR: 0.46; CI: 0.4–0.51) than non‐pregnant adult patients. The most common imaging found in pregnant women is ground‐glass opacity (57%) and in non‐pregnant patients is consolidation (76%). Pregnant women have higher proportion of leukocytosis (27% vs. 14%), thrombocytopenia (18% vs. 12.5%) and have lower proportion of raised C‐reactive protein (52% vs. 81%) compared with non‐pregnant patients. Leucopenia and lymphopenia are almost the same in both groups. The most common comorbidity in pregnant patients is diabetes (18%) and in non‐pregnant patients is hypertension (21%). Case fatality rate (CFR) of non‐pregnant hospitalized patients is 6.4% (4.4–8.5), and mortality due to all‐cause for pregnant patients is 11.3% (9.6–13.3). Regarding the complications of pregnancy, postpartum hemorrhage (54.5% [7–94]), caesarean delivery (48% [42–54]), preterm labor (25% [4–74]) and preterm birth (21% [12–34]) are in turn the most prevalent complications. Comparing the pregnancy outcomes show that caesarean delivery (OR: 3; CI: 2–5), low birth weight (LBW) (OR: 9; CI: 2.4–30) and preterm birth (OR: 2.5; CI: 1.5–3.5) are more probable in pregnant woman with COVID‐19 than pregnant women without COVID‐19. The most prevalent neonatal complications are neonatal intensive care unit admission (43% [2–96]), fetal distress (30% [12–58]) and LBW (25% [16–37]). The rate of vertical transmission is 5.3% (1.3–16), and the rate of positive SARS‐CoV‐2 test for neonates born to mothers with COVID‐19 is 8% (4–16). Overall, pregnant patients present with the similar clinical characteristics of COVID‐19 when compared with the general population, but they may be more asymptomatic. Higher odds of caesarean delivery, LBW and preterm birth among pregnant patients with COVID‐19 suggest a possible association between COVID‐19 infection and pregnancy complications. Low risk of vertical transmission is present, and SARS‐CoV‐2 can be detected in all conception products, particularly placenta and breast milk. Interpretations of these results should be done cautiously due to the heterogeneity between studies; however, we believe our findings can guide the prenatal and postnatal considerations for COVID‐19 pregnant patients.

Major human pathogenic coronaviruses are severe acute respiratory syndrome coronavirus 1 (SARS-CoV-1), Middle East respiratory syndrome coronavirus (MERS-CoV) and the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). 1 Horizontal transmission of SARS-CoV-2 occurs via aerosolized droplets or through contact with infected surfaces, potentially leading to the coronavirus disease 2019 . 2 SARS-CoV-2 is more contiguous than SARS-CoV-1 and MERS-CoV. 3 All demographics are susceptible to SARS-CoV-2; pregnant women are no exception. Respiratory and immune system adaptations during pregnancy increase the risk of acquiring pneumonia and developing severe complications. 4, 5 Pregnancy makes women more susceptible to severe infection by infectious agents such as influenza virus. 6 Influenza vaccine was shown to decrease birth outcomes involving preterm birth and low birth weight (LBW). 7 To protect the fetus from maternal immune responses, alterations in the immune system are necessary, which include decreased number and activity of T cells (both CD4+ and CD8+) and natural killer cells and decreased T-cell proliferation, [8] [9] [10] as well as pregnancy-related hormones that are speculated to weaken cellular immunity. 11 Cardiopulmonary alterations such as increased heart rate and stroke volume and decreased residual capacity may also play an important role in vulnerability of pregnant women to respiratory infections. Decreased functional residual capacity occurs due to anatomical changes in diaphragm and thorax and stimulation of the central respiratory centre via hormonal changes, such as increased corticosteroid aimed at increasing ventilation, but they can cause hypoxia and decreased respiratory capacity in an acute lung injury such as pneumonia. 12 SARS-CoV-1 was linked to complications related to severe infection and a higher mortality rate in pregnant women compared to non-pregnant patients. 13, 14 Similarly, an increased risk for severe COVID-19 among pregnant women compared with non-pregnant women has also been reported. 15 SARS-CoV-1 was also reported to cause obstetric complications such as spontaneous abortion, preterm delivery and intrauterine growth restriction. 13, 16 Of note, animal models evidenced that expression and activity of angiotensin-converting enzyme 2 (ACE2), the main receptor for SARS-CoV-2, increase in kidney, uterus and placenta during pregnancy. 17 Thus, it can be hypothesized that reproductive organs are potential targets for SARS-CoV-2. Impact of SARS-CoV-2 infection on pregnancy outcomes have not been consistently reported. Women infected with SARS-CoV-2 were reported to show elevated rates of obstetric complications such as caesarean delivery and preterm birth. 18, 19 However, there are reports that indicated no significant difference between SARS-CoV-2 infection and adverse outcomes of pregnancy. 20, 21 By conducting a large-scale meta-analysis of reports on SARS-CoV-2 infection, we aimed to provide comprehensive data regarding pregnant patients.

We quantified clinical, laboratory and imaging features of the SARS-CoV-2 infection in addition to pregnancy-related characteristics and outcomes of pregnant women. To assess the impact of SARS-CoV-2 on pregnancy, comparison between pregnant women and control groups was performed, whenever data were available.

Another concern is the vertical transmission from the mother to the fetus or neonate during perinatal period that needs to be addressed. Since the beginning of the SARS-CoV-2 outbreak, several studies have been published regarding mother-to-infant transmission, [22] [23] [24] [25] but the risk of vertical transmission in the population is not clear. This lack of knowledge and subsequent anxiety in patients and clinicians might be an explanation for the high prevalence of preterm birth and caesarean delivery in COVID-19 patients. 26, 27 In this study, data are provided regarding the rate of the vertical transmission, SARS-CoV-2 detection in neonates born to infected mothers, and viral detection in breast milk and conception products.

This study was conducted according to the Preferred Reporting Items for Systematic Reviews and Meta-Analyses Statement guidelines. 28 We searched all studies published up to October 2020, from the 

Duplicate studies were removed using EndNote X7 (Thomson Reuters). Records were initially reviewed by title and abstract independently by three authors (AP, SG and MR). The full text of potentially eligible records was retrieved and examined, and any disagreement was resolved by consensus. 

Studies without the number of confirmed cases, letters to editor, review articles, individual case reports and news reports were excluded. Duplicate data from the same patients were combined and counted as a single case when the data were reported more than one.

All included literatures were published in 2020. The following items were extracted from each article: first author, centre and study location, countries, sample collection time, patient follow-up time, the reference standard for infection confirmation, number of confirmed cases, study type, and all demographic, clinical, radiological, laboratory data, and risk factor data. Two of our authors (SG and MR) independently extracted data, and all extracted data were checked randomly by another author (AP); the differences were resolved by consensus.

Quality assessments of studies were performed by two reviewers independently according to the Critical Appraisal Checklist recommended by the Joanna Briggs Institute, and disagreements were resolved by consensus. The checklist is composed of nine questions that reviewers addressed for each study. The 'Yes' answer to each question received one point. Thus, the final scores for each study could range from 0 to 9 (Table S2 ). 29 

Data cleaning and preparation were done in Microsoft Excel 2010 (Microsoft©), and further analyses were carried out via Comprehensive Meta-Analysis Software Version 2.0 (Biostat). Determination of heterogeneity among the studies was undertaken using the chisquared test (Cochran's Q) to assess the appropriateness of pooling data. We used random-effect model (M-H heterogeneity) for pooled proportion results. 30 Pooled odds ratios (ORs) and 95% confidence intervals (CIs) were calculated from the raw data of the included studies using the random-effects models. Percentages and means ± standard deviations (SDs) were calculated to describe the distributions of categorical and continuous variables, respectively.

p-Values reflect study heterogeneity with <0.05 being significant.

We also used the funnel plot, Begg's and Egger's tests based on the symmetry assumption to detect publication bias ( Figure S1 ).

The process of study selection is represented in Figure 1 Table S3 .

Quality assessment of included studies was performed based on the Critical Appraisal Checklist, and the final quality scores of the included studies are represented in Table S2 . Among 349 included studies, 155 had high quality (8-9 score), 117 medium (6-7 score), and 77 study had low (score 5) or unknown quality. For example, studies by Chen, 31 Wang, 32 Huang, 33 Guan, 34 Zhang, 35 Cheng, 36 Li, 37 Xu 38 and Song 39 had the highest quality of the COVID-19 studies available to date in the purpose of this study. 

Overall, 128,176 non-pregnant patients with confirmed COVID-19 infection and 10,000 pregnant COVID-19 patients were included in the meta-analysis. Funnel plots for included studies did not detect significant publication bias ( Figure S1 ). The mean age among 125,360 non-pregnant COVID-19 patients, was 51.2 (95% CI 45-57, p < 0.001), and was 33 (95% CI 28-37, p < 0.001) among 3348 pregnant COVID-19 patients. Dysgeusia was the third most common symptom presenting in non-pregnant COVID-19 27% (95% CI 10-53, p = 0.9). Also, fatigue was the fourth most common symptom in non-pregnant COVID-19 26 .5% (95% CI 24-30, p < 0.001), while it was less common in pregnant COVID-19 21% (95% CI 17-25.5, p < 0.001) patients. Chill was the fourth most common symptom detected in 25% (95% CI 17-87, p = 0.03) of pregnant patients. Anosmia was found in 25% (95% CI 11-48, p = 0.9) of non-pregnant COVID-19, while it is found in 13.5% (95% CI 5-31.5, p < 0.001) of pregnant COVID-19 patients.

The mean body temperature was 37.2 (95% CI 37.1-37.3, p = 0.1) among non-pregnant COVID-19 patients, and it was 36.7 (95% CI 33-38.5, p < 0.001) among pregnant COVID-19 patients. Hemoptysis was found in 3% (95% CI 1.5-4.5, p < 0.001) among non-pregnant COVID-19 patients, and it was found in 3.5% (95% CI 0.5-19 p = 0.07) among pregnant COVID-19 patients.

Totally, 41% (95% CI 35-52, p < 0.001) of non-pregnant COVID-19 patients and 35% (95% CI 20-54, p < 0.001) of pregnant COVID-19 had contact with another person with respiratory symptoms. Another risk factor for non-pregnant COVID-19 was health care worker by 22 .5% (95% CI 9-43, p < 0.001), in comparison to 17% (95% CI 6.5-31, p = 0.02) in pregnant COVID-19. The most common comorbidity for non-pregnant COVID-19 was hypertension in 21% (95% CI 16-25, p < 0.001), in comparison to 9% (95% CI 8-10, p < 0.001) in pregnant COVID-19. Diabetes was the most common comorbidity for pregnant COVID-19 in 18% (95% CI 11-27, p = 0.4) in comparison to non-pregnant COVID-19 was 11% (95% CI 7.5-14.5, p < 0.001). In addition, non-gestational diabetes and gestational diabetes among pregnant patients with COVID-19 were 8% (95% CI 4.5-13, p < 0.001) and 10% (95% CI 7.5-13.5, p = 0.07), respectively.

Bacterial co-infection occurred in non-pregnant COVID-19 in 4.3% (95% CI 1.4-11, p < 0.001), compared to 16% (95% CI 2.5-61, p < 0.001) in pregnant COVID-19. Viral co-infection occurred in nonpregnant COVID-19 in 4.5% (95% CI 2-11, p < 0.001) patients, when compared to pregnant COVID-19 14% (95% CI 7.5-25, p = 0.6).

The analysis showed that 83.5% (95% CI 77-80, p < 0.001) of non- Also, abnormal chest x-ray findings in neonates were found in 49% (95% CI 13-41, p = 0.09) ( Table 1 ).

Based on the available data, the case fatality rate (CFR) of nonpregnant COVID-19 hospitalized patients was 6.4% (95% CI 4.4-8.5, p < 0.001). For pregnant patients, the CFR was not possible to report based on the original article; however, death from all-cause in pregnant women with COVID-19 was calculated 11.3% (95% CI 9.6-13.3, I 2 82%). Abbreviations: ALT, alanine aminotransferase; AST, aspartate aminotransferase; CRP, C-reaction protein, n = number of variable, N= number of total case or control; PMH, past medical history. * Increased or decreased refers to values above or below the normal range. ** Greater than 50% is considered high heterogeneity, less than 50% is considered low heterogeneity. *** A low p-value (<0.05) is consistent with high heterogeneity.

The laboratory findings showed that among non-pregnant COVID-19 patients where data were available, mean count of leucocytes (white blood count [WBC]) was 6 � 10⁹ per L (95% CI 5-7.2) which is less than pregnant COVID-19 that was 8 � 10⁹ per L (95% CI 7.2-8.8).

Also, the WBC was increased in 14% of non-pregnant patients and 27% of pregnant COVID-19 cases. WBC count was decreased in 25.5% of non-pregnant patients which was almost the same as in pregnant patients. Among non-pregnant COVID-19 patients, the mean count of neutrophil was 4.3 � 10⁹ per L (95% CI 3.5-8.5), which was less than pregnant COVID-19, 6.6 � 10⁹ per L (95% CI 4.6-8.2).

The platelet count was decreased in 12.5% and 18% of non-pregnant and pregnant patients, respectively. D-dimer level was elevated in both groups, but it was higher in pregnant (3.5 mcg/ml, 95% CI:

1.4-5.5) than non-pregnant (2.5 mcg/ml, 95% CI: 0.8-5.5). C-reactive protein (CRP) was increased in 81% and 52% of non-pregnant and pregnant patients, respectively (Table 3 ).

Medical comorbidities were present in 33% (95% CI 20-48, (Table 4 ).

Fetal distress reported in 16% (95% CI 7-32, p = 0.046), fetal tachycardia in 10% (95% CI 7.5-15, p < 0.99), neonatal death in 2.5% (95% CI 1.5-6, p < 0.6), stillbirth in 4% (95% CI 1.5-10, p < 0.036), LBW (<2500 g) in 25% (95% CI 16-37, p < 0.001), mean of 1 min APGAR score was 9 (95% CI 8-10, p = 0.9), mean of 5 min APGAR score was 10 (95% CI 9-10.7, p = 0.9), neonatal asphyxia in 4% (95% CI 1.5-9, p = 0.8), vertical transmission in 5.3% (95% CI 13-16, p = 0.3), neonatal symptoms was found among 33% (95% CI 13-62, p < 0.001) of 579 cases, neonates with confirmed COVID-19 were 8% (95% CI 4-16, p < 0.78) and COVID-19 negative children were 68% (95% CI 57-78, p < 0.001). Breast feeding in 38% (95% CI 20-61, p < 0.001), formula feeding in 56% (95% CI 28.5-80, p < 0.001), mixed feeding in 39% (95% CI 2.5-94, p < 0.001) of cases were reported. SARS-CoV-2 reported to detect in 12% (95% CI 5-26, p < 0.3) of placenta specimens, in 5% (95% CI 2-11, p < 0.26) of breast milk, in 5.6% (95% CI 2-15, p < 0.8) of amniotic fluid, in 6% (95% CI 2-12.5, p < 0.9) of umbilical cord and in 4.6% (95% CI 1.6-12.5, p < 0.5) of vaginal secretions (Table 4 ). Based on a report by the CDC, most prevalent symptoms in patients with COVID-19 in the general population were cough (84%), fever (80%), myalgia (63%), chills (63%), fatigue (62%), headache (59%) and shortness of breath (57%). 40 Our results revealed that fever (75.5%) and cough (48.5%) were the most common clinical symptoms observed in both pregnant women and non-pregnant patients with COVID-19. They were followed by myalgia and chill in pregnant women and dysgeusia and fatigue in non-pregnant patients.

Fever and cough were also reported by other meta-analyses as the most common manifestations of COVID-19 in pregnant women. 19, 41, 42 Based on our analysis, pregnant women with COVID-19 manifested fever with similar odds to non-pregnant women with COVID-19; however, they were less likely to show cough, fatigue, sore throat, headache and diarrhoea. The lower probability of common symptoms of COVID-19 in pregnant women, shown by our results and another meta-analysis, 19 suggests a more asymptomatic course of the disease in pregnancy.

Our analysis showed that from every three pregnant patients with COVID-19, approximately one patient had pre-existing comorbidities. The most common comorbidities were diabetes (including gestational and non-gestational diabetes) and bacterial co-infection in pregnant patients. History of diabetes was also more common in pregnant women with COVID-19 compared with non-pregnant women with the disease in a different meta-analysis. 19 Our results showed that both bacterial and viral co-infection were more prevalent among pregnant women than in non-pregnant patients. These findings can be related to the relative immunosuppression status due to pregnancy as well as the immunocompromised state during JAFARI ET AL. SARS-CoV-2 infection. Co-infection in pregnant women may be the reason of the observed laboratory changes such as leucocytosis and elevated CRP. They may also be linked with adverse pregnancy outcomes such as preterm labour and birth since there are evidence regarding this association. 43 The mean of maternal BMI (32.1 kg/m 2 ) in this study suggests that a considerable number of pregnant patients with COVID-19 were obese. It can be hypothesized that obese patients are more probable to catch the disease in the hospital since they are more possible to admit in the hospital due to obstetric complications. Obesity is a risk factor for almost all pregnancy complications and maternal death. 44 It is also an independent prognostic factor for the severity of COVID-19. 45 A report from the CDC also indicated a high frequency of chronic lung disease, diabetes mellitus and cardiovascular disease among pregnant patients with COVID-19. 46 Regardless of the possible impairment of the immune system in pregnancy, our results indicate that comorbidities likely play a role in acquiring the infection and developing complications.

show similar imaging lesions with non-pregnant patients. In contrast, GGOs were more common than consolidation in pregnant women.

GOO was reported by another meta-analysis as the most common imaging finding in pregnant patients. 41 In another study, clinical and imaging parameters were retrospectively reviewed and compared between pregnant patients and non-pregnant patients with COVID-19. The results showed higher frequent consolidation including mixed GGO with consolidation and complete consolidation in the pregnant group compared to the non-pregnant adults that are inconsistent with our results which may be due to a smaller number of patients in their study. 47 In a large group of patients with COVID-19 from the general population, the most prevalent laboratory findings were increased CRP (73.6%), decreased albumin (62.9%), increased erythrocyte sedimentation rate (61.2%), decreased eosinophils (58.4%), increased interleucin-6 (53.1%), lymphopenia (47.9%) and increased lactate Increased and decreased refer to values above or below the normal range, respectively. Some normal ranges can be different in the different age and sex groups.

T A B L E 4 Meta-analysis: characteristics and obstetric and neonatal outcomes of pregnant patients with confirmed COVID-19 D-Dimer levels were elevated in both groups, but were higher in pregnant women (3.5 mcg/ml vs. 2.5 mcg/ml). Lymphopenia and raised CRP were most commonly reported by other meta-analyses of pregnant patients. 19, 41 Somehow consistent with our findings, another study reported that elevated leucocyte and neutrophil counts were more common in pregnant patients comparing with nonpregnant adults. In the same study, no significant difference was observed for lymphopenia between groups. 47 The findings of another study, more consistent with our results, reported elevated inflammatory markers such as WBC, neutrophil, CRP, procalcitonin and D-dimer were significantly higher in pregnant women, whereas mean F I G U R E 2 Meta-analysis forest plot, association of caesarean delivery in COVID-19 pregnant women (case) and COVID-19 non-pregnant women (control) F I G U R E 3 Meta-analysis forest plot, association of history of low birth weight (<2500 gr) in COVID-19 pregnant women (case) and COVID-19 non-pregnant women (control) lymphocyte percentage was lower than in non-pregnant women. 50 Physiologic alterations in laboratory values during pregnancy may influence the interpretation of the values of pregnant women with COVID-19. Elevated leucocyte counts, particularly neutrophil count, lymphocytopenia and thrombocytopenia are expected changes in pregnant women. 51 Furthermore, CRP values have been shown to be elevated in pregnant women than non-pregnant persons and may further elevate during labour. 52 In our meta-analysis, the CFR for non-pregnant adult patients with COVID-19 was 6.4%. Reports from different populations on COVID-19 CFR varied from 0 to 20%; however, the estimated overall CFR was close to our study around 4%. 53 In women infected by SARS-CoV-1, the mortality rate appeared higher in those affected in pregnancy compared with non-pregnant women. 14, 54 The CFR for all reported mortality cases of pregnant women due to SARS and MERS were 15% and 27%, respectively. 55 In the present meta-analysis, mortality from all-cause in 2660 pregnant patients with COVID-19 was 11.3%, which was markedly higher than 0.1% in another metaanalysis of 11,580 women. 19 Various factors may be the source of the observed difference such as high heterogeneity of the values in the two studies (I 2 : 82% in the current study and I 2 : 80.2% in the second study). Moreover, a significant proportion of some of the known risk factors for maternal mortality was observed in our study. History of medical comorbidities, obesity, gravidity and prior caesarean delivery are maternal characteristic that were shown to be predictors of maternal death. 56 The most common obstetric outcomes based on our analysis were postpartum haemorrhage, caesarean delivery, preterm labour and preterm birth, respectively. Compared to women without COVID-19, preterm birth, caesarean delivery and LBW were more probable in women with COVID-19 and low or absent heterogeneity were observed between studies. Higher odds of preterm birth (OR = 3.01) in women with COVID-19 compared to women without the disease was reported by another meta-analysis. They did not find a difference for other maternal outcomes between groups. 19 Preterm delivery and birth weight did not show a significant association with COVID-19 in pregnant women in another meta-analysis and they reported a lack of between-study heterogeneity (I 2 = 0%). 21 Caesarean delivery in our meta-analysis occurred in almost half of the patients. It was also shown to be higher by another meta-analysis (pooled proportion of 89%). 42 Indications for the caesarean section were not clear in most of the reports to show if they were due to medical indications. In this context, a systematic review of the pregnant COVID-19 cases reported a high proportion of preterm birth by caesarean delivery. Among cases with the available indications for caesarean delivery, 55.9% was due to COVID-19 pneumonia. 27 Therefore, there is an urgent need to address these issues. Higher proportions of comorbidities in pregnant patients could have predisposed them to elevated risk for pregnancy complications in addition to a higher risk for incidence and severity of the COVID-19. Inconsistent with the current study, a large-scale cohort observed no significant difference in pregnancy complications among patients with SARS-CoV-2 infection and pregnant women without infection. 20 Neonatal intensive care unit (NICU) admission was shown to have higher odds (OR 3.13) in neonates of pregnant patients with COVID-19 than neonates born to patients without COVID-19 in another meta-analysis. 17 Some reports showed no evidence of vertical transmission and all samples of neonates including throat swab, amniotic fluid, cord blood and breast milk were negative. [57] [58] [59] Conversely, there are reports on the vertical transmission of the COVID-19. [22] [23] [24] [25] The possibility of this type of transmission is still under debate and strong evidence is lacking to support this type of transmission. [57] [58] [59] Real-time polymerase chain reaction (RT-PCR) of nasopharyngeal or anal swabs of infants born to infected mothers was reported. 22, 24 Elevated SARS-CoV-2 IgM and IgG were also observed in the neonates of mothers with COVID-19, while the results of the RT-PCR were negative for SARS-CoV-2. 60, 61 This result suggests that elevated anti-SARS-CoV-2 antibody is not a strong evidence for vertical transmission due to the possible transfer from mother to infant. The results from our study support that there is a low possibility of vertical transmission in agreement with the results of other meta-analyses. 62 In our study, SARS-CoV-2 was detected in breast milk and all conception products, although with low proportion, suggest them as a route for viral transmission. Other studies reported consistent findings regarding the presence of SARS-CoV-2 in conception products. 25, 62 Based on our results, the pooled proportion of positive SARS-CoV-2 in placental specimens was almost twice than with other specimens.

ACE2 is strongly expressed in maternal-fetal interface involving the placenta and decidua. 63 Therefore, it can be hypothesized that the virus can invade and damage the placenta and increase placental permeability. It may possibly lead to placenta insufficiency and some of the obstetric complications that were reported in women with COVID-19 such as abortion, LBW or preterm birth. Based on the suggestive evidence for direct placenta invasion, caesarean delivery may not significantly decrease the risk of vertical transmission. In this regard, the neonates of the mothers with COVID-19 were assessed for acquiring the infection. It was reported that the risk was low and caesarean delivery and breastfeeding did not increase the risk. 64 Moreover, in most studies, infants with positive test results for SARS-CoV-2 were asymptomatic or developed mild symptoms. 22, 60, 61, 64 In conclusion, this meta-analysis provided valuable information regarding COVID-19 in the pregnant women and clarified that they are at a potential higher risk for pregnancy complications. We 

Several limitations exist for this study. Publication bias and study heterogeneity are unavoidable in this type of study; therefore, it JAFARI ET AL. should be considered when interpreting the final data set. Further, this study may overestimate disease severity due to lack of screening of asymptomatic or mildly symptomatic individuals and subsequent publication bias related to these factors. Journal bias is another issue facing those who carry out meta-analysis, yet it does not usually affect the general conclusions. Also, the possibility of the occurrence of other biases such as choice bias cannot be rejected.

None.

Severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2): an update

Genomic characterisation and epidemiology of 2019 novel coronavirus: implications for virus origins and receptor binding

Pneumonia in pregnancy

What are the risks of COVID-19 infection in pregnant women?

Pregnancy and infection

The effects of influenza vaccination during pregnancy on birth outcomes: a systematic review and meta-analysis

Physiologic adaptations of pregnancy

Mechanisms of diminished natural killer cell activity in pregnant women and neonates

The thymus in pregnancy: the interplay of neural, endocrine and immune influences

Cell-mediated immunity and pregnancy

Pneumonia in pregnant women: exploring this high risk complication& its links to preterm labor

Potential maternal and infant outcomes from (Wuhan) coronavirus 2019-nCoV infecting pregnant women: lessons from SARS, MERS, and other human coronavirus infections

A case-controlled study comparing clinical course and outcomes of pregnant and non-pregnant women with severe acute respiratory syndrome

Update: characteristics of symptomatic women of reproductive age with laboratory-confirmed SARS-CoV-2 infection by pregnancy status-United States

Pregnancy and perinatal outcomes of women with severe acute respiratory syndrome

ACE2 expression and activity are enhanced during pregnancy

Characteristics and outcomes of 241 births to women with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection at five New York City medical centers

Clinical manifestations, risk factors, and maternal and perinatal outcomes of coronavirus disease 2019 in pregnancy: living systematic review and meta-analysis

Pregnancy outcomes among women with and without severe acute respiratory syndrome coronavirus 2 infection

COVID-19 infection in pregnant women, preterm delivery, birth weight, and vertical transmission: a systematic review and meta-analysis

Severe COVID-19 during pregnancy and possible vertical transmission

Vertical transmission of SARS-CoV-2: what is the optimal definition?

Neonatal early-onset infection with SARS-CoV-2 in 33 neonates born to mothers with COVID-19 in Wuhan, China

Analysis of SARS-CoV-2 vertical transmission during pregnancy

Why are pregnant women susceptible to COVID-19? An immunological viewpoint

Coronavirus disease 2019 during pregnancy: a systematic review of reported cases

Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement

The development of software to support multiple systematic review types: the Joanna Briggs Institute system for the Unified Management, assessment and review of information (JBI SUMARI)

Statistical aspects of the analysis of data from retrospective studies of disease

Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study

Clinical characteristics of 138 hospitalized patients with 2019 novel coronavirus-infected pneumonia in Wuhan, China

Clinical features of patients infected with 2019 novel coronavirus in Wuhan

Clinical characteristics of coronavirus disease 2019 in china

Clinical characteristics of 140 patients infected with SARS-CoV-2 in Wuhan

Kidney disease is associated with inhospital death of patients with COVID-19

Early transmission dynamics in wuhan, china, of novel coronavirus-infected pneumonia

Clinical findings in a group of patients infected with the 2019 novel coronavirus (SARS-Cov-2) outside of Wuhan, China: retrospective case series

Emerging 2019 novel coronavirus (2019-nCoV) pneumonia

Symptom profiles of a convenience sample of patients with COVID-19 -united states

Clinical presentation and outcomes of pregnant women with coronavirus disease 2019: A systematic review and meta-analysis

COVID-19 in pregnant women: A systematic review and meta-analysis

The role of infection in preterm labour and delivery

Obesity in Pregnancy: Implications for the mother and lifelong health of the child. A consensus statement

Obesity as a predictor for a poor prognosis of COVID-19: A systematic review

Characteristics of women of reproductive age with laboratory-confirmed SARS-CoV-2 infection by pregnancy status -united states

Clinical and CT imaging features of the COVID-19 pneumonia: Focus on pregnant women and children

Laboratory findings of COVID-19: a systematic review and meta-analysis

Epidemiologic, clinical, and laboratory findings of the COVID-19 in the current pandemic: systematic review and meta-analysis

Clinical characteristics and laboratory results of pregnant women with COVID-19 in Wuhan, China

Physiological changes in hematological parameters during pregnancy. Indian

C-reactive protein in normal pregnancy

Explaining among-country variation in COVID-19 case fatality rate

225-Management guidelines for obstetric patients and neonates born to mothers with suspected or probable severe acute respiratory syndrome (SARS)

Coronavirus in pregnancy and delivery: rapid review

Predictors of maternal mortality and near-miss maternal morbidity

Clinical characteristics and intrauterine vertical transmission potential of COVID-19 infection in nine pregnant women: a retrospective review of medical records. The Lancet

Clinical analysis of 10 neonates born to mothers with 2019-nCoV pneumonia

Coronavirus disease 2019 in pregnant women: a report based on 116 cases

Possible Vertical Transmission of SARS-CoV-2 From an Infected Mother to Her Newborn

Antibodies in infants born to mothers with COVID-19 pneumonia

Vertical transmission of coronavirus disease 2019: a systematic review and meta-analysis

The SARS-CoV-2 receptor ACE2 expression of maternal-fetal interface and fetal organs by single-cell transcriptome study

Maternal transmission of SARS-COV-2 to the neonate, and possible routes for such transmission: a systematic review and critical analysis

Clinical characteristics and outcomes of pregnant women with COVID-19 and comparison with control patients: A systematic review and meta-analysis

The authors declare no competing interests.